Spinomix on the way to commercial maturity20.06.2014 09:09
Spinomix is currently in several discussions with key diagnostics players and life sciences equipment suppliers for the licensing and commercialization of its first products. Last week Spinomix has appointed Peter Hirth to its Board of Directors. He has the experience and network to guide the Swiss start-up through to commercial maturity.
Spinomix is building the new gold standard for sample processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety.
Spinomix’ products MagPhase and FibroTrap improve the sensitivity and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse. The company is conducting validation programmes of these products with key market players in research and industry with the goal of developing partnerships for their commercialisation.
Last week Spinomix has now appointed a person to its Board of Directors with the experience and network to guide the Swiss start-up through to commercial maturity. Peter Hirth has a Track record as one of biopharmaceutical sector’s most successful drug developers and CEOs.
“We are delighted that an industry leader such as Dr.Hirth has joined our Board. He has an outstanding track record in the sector and his counsel will prove invaluable as we develop Spinomix towards commercial maturity,” said Heiner Dreismann, Ph.D., Chairman of the Board.
“Spinomix has the potential to transform the current industry standards and practice for the processing of biochemical substances by improving the sensitivity and turnaround time for critical biomarkers. This will dovetail into the sector’s broad ongoing diagnostic efforts and further support the personalized medicine approaches to improve human health. This is an exciting opportunity to help such an innovative young company optimise its technology and product offerings by building partnerships with the cutting-edge leaders in the life sciences industry,” commented Hirth.
“Spinomix is currently in several discussions with key diagnostics players and life sciences equipment suppliers for the licensing and commercialization of our products MagPhase and FibroTrap. It is a privilege to have somebody of Dr. Hirth’s stature to accompany us on this challenging journey,” stated Nasri Nahas, Chief Executive Officer.
About K. Peter Hirth, Ph.D.
Dr. Hirth currently serves as a Board member of KineMed, Kolltan and Alios Biopharma. From 2001 to 2013 Dr. Hirth served as co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which over the last ten years, has brought several new chemical entities (NCEs) into the clinic in a variety of indications. The most advanced therapeutic from this portfolio is a V600E B-raf selective inhibitor that was FDA approved for metastatic melanoma together with a companion diagnostic and is sold under the brand name Zelboraf. Plexxikon was acquired in April 2011 by Daiichi Sankyo.